Select Language
Free Registration

Solutions for RSV vaccine and drug development

Human Respiratory Syncytial Virus, (HRSV) is a negative-stranded RNA virus of the Pneumoviridae family (genus Orthopneumovirus) that can inflict potentially deadly respiratory tract infections in infants, the elderly, and immunocompromised individuals leading to approximately 50,000 deaths of children under 5 per year.

The HRSV genome is about 15.2kb in length and encodes for 11 proteins. RSV surface fusion protein (F) and attachment (G) glycoproteins play important roles in mediating infection and are both major targets of the humoral immune response. RSV F is well conserved while G is highly variable, with the two antigenic subgroups of RSV (A and B) being defined primarily by differences in the G protein. Vaccine and therapeutics development efforts have largely focused on RSV F.

Solutions for RSV vaccine and drug development
Solutions for RSV vaccine and drug development

（10.1038/s41579-019-0149-x）

RSV F is a type I fusion protein that rearranges from a metastable prefusion conformation to a highly stable postfusion structure. Based on the structural research on RSV F protein, there are at least 7 different antigenic epitopes that have been identified, termed Site Ø, I, II, III, IV, V, and a quaternary dependent (QD) site. Of these sites, only I, II, and IV are exposed on the post-F form. The post-F form has been found to elicit relatively weaker neutralizing antibodies that fail to stop infection. The pre-fusion form has been proven to induce more efficient neutralizing antibodies, while the post-fusion form can be used as a control for screening for pre-specific antibody.
The epitopes of RSV-F protein and antibody binding
The epitopes of RSV-F protein and antibody binding
ACROBiosystems provides comprehensive solutions to support RSV vaccine and drug development efforts!

RSV vaccines and drugs R&D solutions

Main Features

Specially designed natural conformation: Specially designed trimeric Pre-F protein, Post-F protein, and G protein with natural trimeric conformation.

Rich product types: Covers RSV Pre-F, Post-F and G proteins with correct conformation, RSV-F0 broad-spectrum antibodies and Pre-F0 specific antibodies, Pre-F0 antigen and antibody detection kits;

High purity: Purity >90% verified by SDS-PAGE and SEC-MALS.

High activity: Strong binding ability of Pre-F and Post-F proteins to their specific antibodies verified by ELISA.

High immunogenicity: Natural conformation RSV-F and G proteins can induce higher antibody titers.

Assay Data

Natural trimeric Pre-F protein validation data
SEC-MALS verified Pre-F trimeric protein purity >90%
Natural trimeric Pre-F protein validation data

The purity of HRSV (A) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) is more than 90% and the molecular weight of this protein is around 175-200 kDa verified by SEC-MALS.

ELISA verified Pre-F trimeric protein binding with Pre-F specific antibody (D25) linear range 0.2-1 ng/mL
Natural trimeric Pre-F protein validation data

Immobilized HRSV (A) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 2 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (D25) with a linear range of 0.2-1 ng/mL (QC tested).

Pre-F specific antibody product validation data
ELISA verified Pre-F specific antibody 12C6 can specifically recognize Pre-F trimer, not binding to Post-F trimer
Pre-F specific antibody product validation data

Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-Pre-F0 specific Antibody, Human IgG1 (12C6) (Cat. No. RS0-S286) with a linear range of 0.2-2 ng/mL. HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) is verified not recoginized by Monoclonal Anti-RSV-Pre-F0 specific Antibody, Human IgG1 (12C6) (Cat. No. RS0-S286) in low concentration (QC tested).

ELISA Detection Kits
ELISA Detection Kits

Detection of Pre-Fusion glycoprotein F0 (RSV) by sandwich-ELISA Assay.Immobilized Anti-Pre-Fusion glycoprotein F0 (RSV) Antibody can bind Pre-Fusion glycoprotein F0 (RSV). Detection was performed using HRP-Anti-Pre-Fusion glycoprotein F0 (RSV) Antibody with sensitivity of 3.1 ng/mL (QC tested).

Resources

Resources
Solutions for RSV vaccine and drug development
Analytical Methods to Identify Structural Conformation of RSV Pre- and Post-fusion Proteins for Vaccine Development
  • Background
  • RSV vaccines and drugs R&D solutions
  • Main Features
  • Assay Data
  • Resources